 Masanori Hayashi
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Ewing | 10 | 2026 | 102 | 3.580 |
Why?
| | Bone Neoplasms | 12 | 2026 | 253 | 2.480 |
Why?
| | Biomarkers, Tumor | 7 | 2025 | 1313 | 1.120 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 62 | 0.880 |
Why?
| | Clonal Evolution | 1 | 2025 | 47 | 0.860 |
Why?
| | Wnt Signaling Pathway | 2 | 2024 | 210 | 0.820 |
Why?
| | Hindlimb | 2 | 2024 | 131 | 0.820 |
Why?
| | Hydrogen | 1 | 2024 | 73 | 0.800 |
Why?
| | Cadherins | 1 | 2024 | 201 | 0.750 |
Why?
| | beta Catenin | 2 | 2024 | 252 | 0.740 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 4 | 2026 | 29 | 0.740 |
Why?
| | RNA-Binding Protein EWS | 4 | 2026 | 30 | 0.740 |
Why?
| | Circulating Tumor DNA | 2 | 2024 | 43 | 0.710 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 358 | 0.700 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2024 | 1137 | 0.690 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 86 | 0.670 |
Why?
| | Osteosarcoma | 5 | 2024 | 76 | 0.670 |
Why?
| | Pituitary Diseases | 1 | 2020 | 20 | 0.660 |
Why?
| | Reperfusion Injury | 1 | 2024 | 300 | 0.660 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2020 | 36 | 0.650 |
Why?
| | Oncogene Proteins, Fusion | 4 | 2026 | 210 | 0.640 |
Why?
| | Pituitary Gland | 1 | 2020 | 148 | 0.630 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 225 | 0.570 |
Why?
| | DNA, Neoplasm | 2 | 2023 | 163 | 0.510 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4557 | 0.440 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 42 | 0.440 |
Why?
| | Neoplastic Cells, Circulating | 3 | 2025 | 81 | 0.420 |
Why?
| | Muscle, Skeletal | 1 | 2024 | 1795 | 0.400 |
Why?
| | Thrombocytopenia | 1 | 2015 | 205 | 0.380 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2026 | 1953 | 0.370 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 257 | 0.370 |
Why?
| | Anti-Infective Agents | 1 | 2015 | 242 | 0.360 |
Why?
| | Precision Medicine | 1 | 2016 | 457 | 0.360 |
Why?
| | Hydroxyurea | 1 | 2011 | 34 | 0.350 |
Why?
| | Transfusion Reaction | 1 | 2011 | 63 | 0.340 |
Why?
| | Prognosis | 7 | 2025 | 4282 | 0.340 |
Why?
| | Tumor Microenvironment | 4 | 2025 | 732 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2025 | 1455 | 0.300 |
Why?
| | Sarcoma | 4 | 2024 | 205 | 0.290 |
Why?
| | Perioperative Care | 1 | 2011 | 231 | 0.290 |
Why?
| | Translocation, Genetic | 2 | 2021 | 115 | 0.280 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1054 | 0.270 |
Why?
| | Child | 13 | 2025 | 22633 | 0.260 |
Why?
| | Anemia, Sickle Cell | 1 | 2011 | 312 | 0.260 |
Why?
| | Albumins | 2 | 2024 | 118 | 0.250 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2025 | 12 | 0.240 |
Why?
| | Paclitaxel | 2 | 2024 | 255 | 0.230 |
Why?
| | Eflornithine | 1 | 2025 | 8 | 0.230 |
Why?
| | Deoxycytidine | 2 | 2024 | 221 | 0.230 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2025 | 66 | 0.230 |
Why?
| | Polyamines | 1 | 2025 | 42 | 0.230 |
Why?
| | Stromal Cells | 1 | 2025 | 124 | 0.220 |
Why?
| | B7 Antigens | 1 | 2024 | 18 | 0.210 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2025 | 928 | 0.210 |
Why?
| | Mice | 7 | 2025 | 18339 | 0.210 |
Why?
| | Adolescent | 10 | 2026 | 22428 | 0.210 |
Why?
| | Cell Line, Tumor | 4 | 2025 | 3540 | 0.200 |
Why?
| | Interleukin-8 | 1 | 2024 | 271 | 0.200 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2023 | 33 | 0.190 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 442 | 0.190 |
Why?
| | Administration, Inhalation | 1 | 2024 | 574 | 0.180 |
Why?
| | Fertility Preservation | 1 | 2022 | 53 | 0.180 |
Why?
| | Humans | 24 | 2026 | 144759 | 0.180 |
Why?
| | Male | 11 | 2026 | 72315 | 0.180 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1782 | 0.170 |
Why?
| | Liposarcoma, Myxoid | 1 | 2021 | 10 | 0.170 |
Why?
| | Mice, SCID | 3 | 2016 | 369 | 0.170 |
Why?
| | Tumor Cells, Cultured | 3 | 2020 | 919 | 0.170 |
Why?
| | Rhabdomyosarcoma | 2 | 2020 | 64 | 0.160 |
Why?
| | Anti-Inflammatory Agents | 1 | 2024 | 474 | 0.160 |
Why?
| | Mice, Inbred NOD | 3 | 2016 | 610 | 0.160 |
Why?
| | Interleukin-6 | 1 | 2024 | 780 | 0.150 |
Why?
| | Female | 12 | 2026 | 78271 | 0.150 |
Why?
| | Animals | 7 | 2025 | 38058 | 0.150 |
Why?
| | Down-Regulation | 1 | 2021 | 627 | 0.140 |
Why?
| | Neoplasm Metastasis | 2 | 2025 | 688 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 219 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 1 | 2020 | 573 | 0.130 |
Why?
| | Cyclophosphamide | 1 | 2017 | 266 | 0.130 |
Why?
| | Calmodulin-Binding Proteins | 1 | 2016 | 14 | 0.120 |
Why?
| | Bone Marrow Transplantation | 1 | 2017 | 294 | 0.120 |
Why?
| | Cell Proliferation | 3 | 2025 | 2496 | 0.120 |
Why?
| | Radiotherapy | 1 | 2017 | 206 | 0.120 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 34 | 0.120 |
Why?
| | Pyrazines | 1 | 2015 | 92 | 0.110 |
Why?
| | Neoplasms | 2 | 2022 | 2875 | 0.110 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2016 | 381 | 0.110 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 243 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 359 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 732 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3409 | 0.100 |
Why?
| | Transcription Factors | 1 | 2021 | 1741 | 0.090 |
Why?
| | Time Factors | 1 | 2024 | 7173 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 2016 | 462 | 0.090 |
Why?
| | Neoplasm Staging | 1 | 2016 | 1462 | 0.090 |
Why?
| | Glioblastoma | 1 | 2015 | 353 | 0.090 |
Why?
| | Pyridines | 1 | 2015 | 605 | 0.080 |
Why?
| | Flow Cytometry | 1 | 2015 | 1173 | 0.080 |
Why?
| | Young Adult | 6 | 2026 | 14105 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1837 | 0.070 |
Why?
| | Mutation | 1 | 2020 | 4089 | 0.070 |
Why?
| | Clinical Trials as Topic | 3 | 2020 | 1053 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2016 | 1519 | 0.070 |
Why?
| | Child, Preschool | 2 | 2020 | 11787 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2020 | 2452 | 0.070 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2025 | 37 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1318 | 0.060 |
Why?
| | Liquid Biopsy | 1 | 2024 | 13 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1716 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2025 | 364 | 0.050 |
Why?
| | Adult | 6 | 2026 | 40449 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2017 | 11679 | 0.040 |
Why?
| | Immunotherapy | 1 | 2025 | 653 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 337 | 0.040 |
Why?
| | Infant | 1 | 2015 | 10034 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 154 | 0.040 |
Why?
| | HLA Antigens | 1 | 2021 | 225 | 0.040 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2021 | 202 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 332 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2023 | 17066 | 0.040 |
Why?
| | Counseling | 1 | 2022 | 408 | 0.040 |
Why?
| | Transcriptome | 1 | 2025 | 1045 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 241 | 0.040 |
Why?
| | Proteomics | 1 | 2025 | 1195 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2020 | 356 | 0.030 |
Why?
| | Selection, Genetic | 1 | 2020 | 256 | 0.030 |
Why?
| | Transplantation, Haploidentical | 1 | 2017 | 23 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2020 | 457 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 851 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 582 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1982 | 0.030 |
Why?
| | Biological Evolution | 1 | 2020 | 488 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2016 | 194 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2016 | 133 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 143 | 0.030 |
Why?
| | Graft Survival | 1 | 2017 | 526 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1266 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 983 | 0.020 |
Why?
| | Macrophages | 1 | 2021 | 1511 | 0.020 |
Why?
| | Cell Survival | 1 | 2015 | 1098 | 0.020 |
Why?
| | Prospective Studies | 1 | 2024 | 7990 | 0.020 |
Why?
| | Middle Aged | 2 | 2026 | 35875 | 0.020 |
Why?
| | Patient Care Team | 1 | 2017 | 689 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5408 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2016 | 985 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1560 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8265 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2015 | 3121 | 0.020 |
Why?
| | Apoptosis | 1 | 2016 | 2430 | 0.020 |
Why?
| | Aged | 1 | 2021 | 25913 | 0.010 |
Why?
|
|
Hayashi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|